Skip to main content

Table 2 Incident NTM infection categorized by the year after the diagnosis of SS

From: The risk of nontuberculous mycobacterial infection in patients with Sjögren’s syndrome: a nationwide, population-based cohort study

Variable

Total

Event (%)

Total person-years

Incidence Rate (/105 years)

IRR (95%CI)

The entire period

 Non- SS

98,310

9 (0.01)

312,435

3

1

 SS

6554

4 (0.06)

18,365

22

7.56 (2.33–24.55)

  SS treated without immunosuppressants

5205

1 (0.02)

14,196

7

2.45 (0.31–19.30)

  SS treated with immunosuppressants

1349

3 (0.22)

4169

72

24.98 (6.76–92.27)

 Total

104,864

13 (0.01)

330,800

4

 

1st year

 Non- SS

98,310

3 (0.00)

95,803

3

1

 SS

6554

3 (0.05)

5970

50

16.05 (3.24–79.51)

  SS treated without immunosuppressants

5599

1 (0.02)

5089

20

6.27 (0.65–60.33)

  SS treated with immunosuppressants

955

2 (0.21)

881

227

72.51 (12.12–433.98)

 Total

104,864

6 (0.01)

101,773

6

 
  1. Immunosuppressants: methotrexate, cyclophosphamide, or azathioprine. Abbreviations: SS Sjögren’s Syndrome, CCI Charlson comorbidity index